Allergy/Imm Medical News about Prostate cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Immunotherapy data may signal new era in advanced prostate cancer care
Urology Times, 06/12/09

Kerr RR - Results of a milestone study on the use of an experimental form of immunotherapy may usher in a new era in the management of androgen-independent prostate cancer. If approved by the FDA, the agent, sipuleucel-T (Provenge), could markedly shift the paradigm for treating this most advanced form of the disease. Prostate cancer-specific survival also favored the sipuleucel-T arm of the study. Sipuleucel-T did not significantly delay time to progression, consistent with other trials in this patient population.

<< Previous
Immunogenicity of 23-valent pneumococcal polysaccharide vaccine...

Next >>
Histamine H1-receptor antagonists with immunomodulating...